5-(tetradecyloxy)-2-furancarboxylic acid has been researched along with Carcinoma in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Cohen, MB; Glover, RA; Guseva, NV; Rokhlin, OW | 1 |
1 other study(ies) available for 5-(tetradecyloxy)-2-furancarboxylic acid and Carcinoma
Article | Year |
---|---|
TOFA (5-tetradecyl-oxy-2-furoic acid) reduces fatty acid synthesis, inhibits expression of AR, neuropilin-1 and Mcl-1 and kills prostate cancer cells independent of p53 status.
Topics: Acetyl-CoA Carboxylase; Androgen Receptor Antagonists; Antineoplastic Agents; Apoptosis; Carcinoma; Cell Death; Cell Line, Tumor; Cytochromes c; Dihydrotestosterone; Fatty Acids; Furans; Genes, p53; Humans; Introns; Lipids; Male; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein; Neuropilin-1; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Receptors, Androgen | 2011 |